Erratum: Distinct genital tract HIV-specific antibody profiles associated with tenofovir gel (Mucosal Immunology (2016) 9(3) (821–833), (S1933021922009072), (10.1038/mi.2015.145));Distinct genital tract HIV-specific antibody profiles associated with tenofovir gel

Mucosal Immunology

Volumn 9, Issue 3, 2016, Pages 821-833

  Archary, D ^a   Seaton, K E ^b   Passmore, J S ^a,c,d   Werner, L ^a   Deal, A ^b   Dunphy, L J ^e   Arnold, K B ^e   Yates, N L ^b   Lauffenburger, D A ^e   Bergin, P ^f   Liebenberg, L J ^a   Samsunder, N ^a   Mureithi, M W ^g   Altfeld, M ^h   Garrett, N ^a   Abdool Karim, Q ^a,i   Abdool Karim, S S ^a,i   Morris, L ^a,d   Tomaras, G D ^b  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^e Massachusetts Institute of Technology Cambridge   (United States)

^f INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^g UNIVERSITY OF NAIROBI   (Kenya)

^h UNIVERSITY OF HAMBURG   (Germany)

ⁱ Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; PLACEBO; PROTEIN P66; TENOFOVIR; AGENTS USED INTRAVAGINALLY; ANTIRETROVIRUS AGENT; GP120 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; P24 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS TYPE 1; REVERSE TRANSCRIPTASE, HUMAN IMMUNODEFICIENCY VIRUS 1; RNA DIRECTED DNA POLYMERASE;

ADULT; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; CD4 LYMPHOCYTE COUNT; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GEL; GENITAL SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; PREVALENCE; PRIORITY JOURNAL; SEROCONVERSION; VIRUS LOAD; YOUNG ADULT; CLINICAL TRIAL; DRUG EFFECTS; FEMALE GENITAL SYSTEM; FOLLOW UP; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; METABOLISM; MULTICENTER STUDY; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ADULT; ANTI-RETROVIRAL AGENTS; FEMALE; FOLLOW-UP STUDIES; GENITALIA, FEMALE; HIV ANTIBODIES; HIV CORE PROTEIN P24; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; TENOFOVIR; TREATMENT OUTCOME; VAGINAL CREAMS, FOAMS, AND JELLIES; YOUNG ADULT;

EID: 84964969252     PISSN: 19330219     EISSN: 19353456     Source Type: Journal    
DOI: 10.1038/mi.2016.21     Document Type: Erratum

References (69)

1. Grant, R.M. et al. Preexposurechemoprophylaxis forHIV prevention in men who have sex with men. N. Engl. J. Med. 363, 2587-2599 (2010).
2. Baeten, J.M. et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N. Engl. J. Med. 367, 399-410 (2012).
3. Molina, J.-M. et al. On Demand PrEP With Oral TDF-FTC in MSM: Results of the ANRS Ipergay Trial. In Conference on Retroviruses and Opportunistic Infections (CROI). Abstract 23LB, Seattle, Washington, 23-26 February 2015.
4. Abdool Karim, Q. et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329, 1168-1174 (2010).
5. Marrazzo, J.M. et al. Tenofovir-based preexposure prophylaxis for HIV infection among african women. N. Engl. J. Med. 372, 509-518 (2015).
6. McCormack, S. et al. Pragmatic Open-Label Randomised Trial of Preexposure Prophylaxis: The PROUD Study. In Conference on Retroviruses and Opportunistic Infections (CROI). Abstract 22LB. Seattle, Washington, 23-26 February 2015.
7. Cranage, M. et al. Prevention of SIV rectal transmission and priming of Tcell responses in macaques after local pre-exposure application of tenofovir gel. PLoS Med. 5, e157 (2008).
8. Mureithi, M.W. et al. Preservation HIV-1-specific IFNg+ CD4+ T cell responses in breakthrough infections following exposure to Tenofovir Gel in the CAPRISA 004 microbicide trial. J. Acquir. Immune Defic. Syndr. 60, 124-127 (2012).
9. Curtis, K.A. et al. Delayed maturation of antibody avidity but not seroconversion in rhesus macaques infected with simian HIV during oral pre-exposure prophylaxis. J. Acquir. Immune Defic. Syndr. 57, 355-362 (2011).
10. Laeyendecker, O. et al. Antibody maturation in women who acquire HIV infection while using antiretroviral pre-exposure prophylaxis. J. Infect. Dis. 212, 754-759 (2015).
11. Hare, C.B. et al. Seroreversion in subjects receiving antiretroviral therapy during acute/early HIV infection. Clin. Infect. Dis. 42, 700-708 (2006).
12. O'Sullivan, C.E. et al. Epstein-Barr virus and human immunodeficiency virus serological responses and viral burdens in HIV-infected patients treated with HAART. J. Med. Virol. 67, 320-326 (2002).
13. Payne, H. et al. Reactivity of routine HIV antibody tests in children who initiated antiretroviral therapy in early infancy as part of the Children with HIV Early Antiretroviral Therapy (CHER) trial: A retrospective analysis. Lancet Infect. Dis. 15, 803-809 (2015).
14. Devito, C. et al. Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells. J. Immunol. 165, 5170-5176 (2000).
15. Belyakov, I.M., Ahlers, J.D. & Berzofsky, J.A. Mucosal AIDS vaccines: current status and future directions. Exp. Rev. Vaccines 3, S65-S73 (2004).
16. Smith, A.J. et al. Live simian immunodeficiency virus vaccine correlate of protection: immune complex-inhibitory fc receptor interactions that reduce target cell availability. J. Immunol. 193, 3126-3133 (2014).
17. Li, Q. et al. Live simian immunodeficiency virus vaccine correlate of protection: local antibody production and concentration on the path of virus entry. J. Immunol. 193, 3113-3125 (2014).
18. Tudor, D. et al. HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection: an IgA gene and functional analysis. Mucosal Immunol. 2, 412-426 (2009).
19. Mazzoli, S. et al. HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. Nat. Med. 3, 1250-1257 (1997).
20. Kaul, R. et al. Mucosal IgA in exposed, uninfected subjects: evidence for a role in protection against HIV infection. AIDS 15, 431-432 (2001).
21. Seaton, K.E. et al. HIV-1 specific IgA detected in vaginal secretions of HIV uninfected women participating in a microbicide trial in southern africa are primarily directed toward gp120 and gp140 specificities. PLoS One 9, e101863 (2014).
22. Yates, N.L. et al. HIV-1 gp41 envelope IgA is frequently elicited after transmission but has an initial short response half-life. Mucosal Immunol. 6, 692-703 (2013).
23. Lau, K.S. et al. Multi-scale in vivo systems analysis reveals the influence of immune cells on TNF-A-induced apoptosis in the intestinal epithelium. PLoS Biol. 10, e1001393 (2012).
24. Janes, K.A. et al. A systems model of signaling identifies a molecular basis set for cytokine-induced apoptosis. Science 310, 1646-1653 (2005).
25. Woof, J.M. & Mestecky, J. Mucosal immunoglobulins. Immunol. Rev. 206, 64-82 (2005).
26. Russell, M.W. & Mestecky, J. Humoral immune responses to microbial infections in the genital tract. Microbes Infect. 4, 667-677 (2002).
27. Devito, C. et al. Cross-clade HIV-1-specific neutralizing IgA in mucosal and systemic compartments of HIV-1-exposed, persistently seronegative subjects. J. Acquir. Immune Defic. Syndr. 30, 413-420 (2002).
28. Moja, P. et al. Prognostic value of antibodies to p66 during the course of HIV1 infection. Immunol. Lett. 56, 133 (1997).
29. French, M.A. et al. Isotype-switched immunoglobulin G antibodies to HIV Gag proteins may provide alternative or additional immune responses to 'protective' human leukocyte antigen-B alleles in HIV controllers. AIDS 27, 519-528 (2013).
30. Kersh, E.N. et al. Reduced inflammation and CD4 loss in acute SHIV infection during oral pre-exposure prophylaxis. J. Infect. Dis. 206, 770-779 (2012).
31. Hendrix, C.W. et al. MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments. PLoS One 8, e55013 (2013).
32. Louissaint, N.A. et al. Single dose pharmacokinetics of oral tenofovir in plasma, peripheral blood mononuclear cells, colonic tissue, and vaginal tissue. AIDS Res. Hum. Retroviruses 29, 1443-1450 (2013).
33. Kersh, E.N. et al. Tcell chemo-vaccination effects after repeated mucosal SHIV exposures and oral pre-exposure prophylaxis. PLoS One 6, e19295 (2011).
34. Yates, N.L. et al. Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci. Transl. Med. 6, 228ra39 (2014).
35. Haynes, B.F. et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366, 1275-1286 (2012).
36. Zolla-Pazner, S. et al. Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection. PloS One 9, e87572 (2014).
37. Johansson, M. & Lycke, N.Y. Immunology of the human genital tract. Curr. Opin. Infect. Dis. 16, 43-49 (2003).
38. Li, Z. et al. Transfer of IgG in the female genital tract by MHC class I-related neonatal Fc receptor (FcRn) confers protective immunity to vaginal infection. Proc. Natl Acad. Sci. USA 108, 4388-4393 (2011).
39. Gupta, S. et al. The Neonatal Fc receptor (FcRn) enhances human immunodeficiency virus type 1 (HIV-1) transcytosis across epithelial cells. PLoS Pathog. 9, e1003776 (2013).
40. Ackerman, M.E. et al. Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity. J. Clin. Invest. 123, 2183-2192 (2013).
41. Zhou, M. & Ruprecht, R.M. Are anti-HIV IgAs good guys or bad guys? Retrovirology 11, 109 (2014).
42. Sholukh, A.M. et al. Defense-in-depth by mucosally administered anti-HIV dimeric IgA2 and systemic IgG1 mAbs: Complete protection of rhesus monkeys from mucosal SHIV challenge. Vaccine 33, 2086-2095 (2015).
43. Nicholas, K.J. et al. B cell responses to HIVantigen are a potent correlate of viremia in HIV-1 infection and improve with PD-1 blockade. PLoS One 8, e84185 (2013).
44. Barouch, D.H. et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 482, 89-93 (2012).
45. Wesemann, D.R. et al. Microbial colonization influences early B-lineage development in the gut lamina propria. Nature 501, 112-115 (2013).
46. Anahtar, M.N. et al. Cervicovaginal bacteria are a major modulator of host inflammatory responses in the female genital tract. Immunity 42, 965-976 (2015).
47. Xiao, P. et al. Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J. Virol. 84, 7161-7173 (2010).
48. Letvin, N.L. et al. Immune and genetic correlates of vaccine protection against mucosal infection by SIV in monkeys. Sci. Transl. Med. 3, 81ra36 (2011).
49. Florese, R.H. et al. Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines. J. Immunol. 182, 3718-3727 (2009).
50. Gó mez-Romá n, V.R. et al. Vaccine-elicited antibodies mediate antibodydependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J. Immunol. 174, 2185-2189 (2005).
51. Hessell, A.J. et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449, 101-104 (2007).
52. Barouch, D.H. et al. Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell 155, 531-539 (2013).
53. Bournazos, S. et al. Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell 158, 1243-1253 (2014).
54. Bard, E. et al. Validation of a high sensitive immunoenzymatic assay to establish the origin of immunoglobulins in female genital secretions. J. Immunoassay Immunochem. 23, 145-162 (2002).
55. Mestecky, J., Alexander, R.C., Wei, Q. & Moldoveanu, Z. Methods for evaluation of humoral immune responses in human genital tract secretions. Am. J. Reprod. Immunol. 65, 361-367 (2011).
56. Neutra, M.R. & Kozlowski, P.A. Mucosal vaccines: The promise and the challenge. Nat. Rev. Immunol. 6, 148-158 (2006).
57. Devito, C. et al. Intranasal HIV-1-gp160-DNA/gp41 peptide prime-boost immunization regimen in mice results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity. J. Immunol. 173, 7078-7089 (2004).
58. Duerr, A. Update on mucosal HIV vaccine vectors. Curr. Opin. HIV AIDS 5, 397-403 (2010).
59. Bebell, L.M. et al. Relationship between levels of inflammatory cytokines in the genital tract and CD4+ cell counts in women with acute HIV-1 infection. J. Infect. Dis. 198, 710-714 (2008).
60. Tomaras, G.D. et al. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J. Virol. 82, 12449-12463 (2008).
61. Yates, N.L. et al. Multiple HIV-1-specific IgG3 responses decline during acute HIV-1: implications for detection of incident HIV infection. AIDS 25, 2089-2097 (2011).
62. Liao, H.-X. et al. Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity 38, 176-186 (2013).
63. Liao, H.-X. et al. Antigenicity and immunogenicity of transmitted/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1. J. Virol. 87, 4185-4201 (2013).
64. Gao, F. et al. Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 groupmconsensus envelope glycoprotein. J. Virol. 79, 1154-1163 (2005).
65. Gaschen, B. et al. Diversity considerations in HIV-1 vaccine selection. Science 296, 2354-2360 (2002).
66. Liao, H.-X. et al. A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. Virology 353, 268-282 (2006).
67. Morris, L. et al. Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting. PLoS One 6, e23532 (2011).
68. Tibshirani, R. Regression Shrinkage and Selection via the Lasso. J. R. Stat. Soc. Ser. B 58, 267-288 (1996).
69. Lau, K.S. et al. In vivo systems analysis identifies spatial and temporal aspects of the modulation of TNF-A-induced apoptosis and proliferation by MAPKs. Sci. Signal. 4, ra16 (2011).